WORST OF BARRIER REVERSE CONVERTIBLE LINKED TO WORST OF - FRESENIUS/SANOFI/MERCK & CO. Share Price

Certificat

KNRFDU

CH1248352242

Market Closed - Swiss Exchange 16:20:00 20/09/2023 BST
102.9 CHF +0.49% Intraday chart for WORST OF BARRIER REVERSE CONVERTIBLE LINKED TO WORST OF - FRESENIUS/SANOFI/MERCK & CO.
6 months+8.37%

Static data

Product typeObligations Convertibles
Buy / SellCALL
Underlying SANOFI
Issuer UBS
KNRFDU
ISINCH1248352242
Date issued 22/02/2023
Strike 90.15
Maturity 22/08/2024 (82 Days)
Parity 1 : 1
Emission price 100 CHF
Emission volume N/A
Settlement règlement en espèces
Currency CHF

Technical Indicators

Highest since issue 102.9 CHF
Lowest since issue 94.45 CHF

Company Profile

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Sector
-
More about the company

Ratings for Sanofi

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Sanofi

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
89.76 EUR
Average target price
108.2 EUR
Spread / Average Target
+20.53%
Consensus
  1. Stock Market
  2. Certificates
  3. KNRFDU Certificat